This study will compare a nucleoside reverse transcriptase inhibitor-sparing (NRTI-sparing) regimen (Kaletra + nevirapine) to two nucleoside reverse transcriptase inhibitor-based regimens (Combivir + nevirapine and Combivir + Kaletra). Participants will be randomly assigned to receive one of the following drug combinations: * lopinavir/ritonavir (Kaletra) and nevirapine (Viramune) twice a day; * Combivir (Zidovudine (AZT) plus lamivudine (3TC)) and nevirapine twice a day; * Combivir and lopinavir/ritonavir twice a day.
No linked publications found in PubMed
Inclusion Criteria: * Be HIV-positive * Be at least18 years of age * Have viral load above 5 000 copies/ml * Be likely to comply with the study protocol * Agree not to take, for the duration of the study, any drug that is contraindicated with the study drugs * Agree not to take any medication, including over-the-counter medicine, alcohol, or street drugs without the knowledge and permission of the principal investigator Exclusion Criteria: * Have ever received antiretroviral therapy * Pregnancy or breastfeeding * Have abnormal laboratory tests (see investigator) * Have received an investigational drug within 30 days of study drugs administration * Be receiving systemic chemotherapy * Have an acute illness